Literature DB >> 29297116

The inhibitory effect of dinitrosyl iron complexes (NO donors) on myeloperoxidase activity.

N P Akentieva1, N A Sanina2, A R Gizatullin2, N Y Shmatko2, N S Goryachev2, N I Shkondina2, T R Prikhodchenko2, S M Aldoshin2.   

Abstract

The effect of synthetic analogues of dinitrosyl mononuclear iron complexes (DNICs) with functional sulfur-containing ligands (NO donors) on the activity of myeloperoxidase (MPO) was studied, and their efficiency was evaluated. It was shown that the enzyme MPO is the molecular target of DNICs. It was found that six DNICs inhibited the activity of MPO and one compound potentiated it. The evaluation of their efficiency showed that two DNICs effectively inhibited the activity of MPO by 50% at IC50 = 2 × 10-4 M and IC50 = 5 × 10-7 M.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29297116     DOI: 10.1134/S1607672917060126

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN: 1607-6729            Impact factor:   0.788


  11 in total

Review 1.  Chemistry of nitric oxide relevant to biology.

Authors:  J A McCleverty
Journal:  Chem Rev       Date:  2004-02       Impact factor: 60.622

2.  Nitric oxide modulates the catalytic activity of myeloperoxidase.

Authors:  H M Abu-Soud; S L Hazen
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

3.  X-ray crystal structure and characterization of halide-binding sites of human myeloperoxidase at 1.8 A resolution.

Authors:  T J Fiedler; C A Davey; R E Fenna
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

4.  Serum myeloperoxidase levels independently predict endothelial dysfunction in humans.

Authors:  Joseph A Vita; Marie-Luise Brennan; Noyan Gokce; Shirley A Mann; Marlene Goormastic; Mehdi H Shishehbor; Marc S Penn; John F Keaney; Stanley L Hazen
Journal:  Circulation       Date:  2004-08-23       Impact factor: 29.690

5.  Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.

Authors:  Lemin Zheng; Benedicta Nukuna; Marie-Luise Brennan; Mingjiang Sun; Marlene Goormastic; Megan Settle; Dave Schmitt; Xiaoming Fu; Leonor Thomson; Paul L Fox; Harry Ischiropoulos; Jonathan D Smith; Michael Kinter; Stanley L Hazen
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

6.  Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions.

Authors:  Arun K Thukkani; Jane McHowat; Fong-Fu Hsu; Marie-Luise Brennan; Stanley L Hazen; David A Ford
Journal:  Circulation       Date:  2003-11-24       Impact factor: 29.690

7.  Nicorandil, a Nitric Oxide Donor and ATP-Sensitive Potassium Channel Opener, Protects Against Dystrophin-Deficient Cardiomyopathy.

Authors:  Muhammad Z Afzal; Melanie Reiter; Courtney Gastonguay; Jered V McGivern; Xuan Guan; Zhi-Dong Ge; David L Mack; Martin K Childers; Allison D Ebert; Jennifer L Strande
Journal:  J Cardiovasc Pharmacol Ther       Date:  2016-03-02       Impact factor: 2.457

8.  Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion.

Authors:  Stephan Baldus; Thomas Heitzer; Jason P Eiserich; Denise Lau; Hanke Mollnau; Michelle Ortak; Susan Petri; Britta Goldmann; Hans-Jürgen Duchstein; Jürgen Berger; Udo Helmchen; Bruce A Freeman; Thomas Meinertz; Thomas Münzel
Journal:  Free Radic Biol Med       Date:  2004-09-15       Impact factor: 7.376

Review 9.  Myeloperoxidase and its contributory role in inflammatory vascular disease.

Authors:  Denise Lau; Stephan Baldus
Journal:  Pharmacol Ther       Date:  2006-02-13       Impact factor: 12.310

10.  Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes.

Authors:  Stephan Baldus; Christopher Heeschen; Thomas Meinertz; Andreas M Zeiher; Jason P Eiserich; Thomas Münzel; Maarten L Simoons; Christian W Hamm
Journal:  Circulation       Date:  2003-09-02       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.